{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:25:31Z","timestamp":1770884731217,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Management of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has improved patient survival. However, patient quality of life (QOL) continues to be impacted by disease symptoms and treatment-related adverse events. Patient-reported outcome measures (PROMs) provide evidence of the patient experience. A scoping literature review was conducted to identify and summarize the evidence on PROMs used for patients with CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Embase and MEDLINE databases were searched for publications from 2001 to 2023 that reported PROMs. Ongoing and completed trials listed on ClinicalTrials.gov were also reviewed. Results were summarized according to the PROMs used and the information collected in these PROMs. After screening 6337 records, 208 unique studies were identified with published PRO evidence reporting data from 92 unique PROMs. The most commonly reported PROMs (in \u22655% of publications) were used in 115 studies, of which 45 were exclusively in the frontline setting. The most commonly used PROMs in studies in the frontline setting were variations of European Organisation for Research and Treatment of Cancer QLQ, Functional Assessment of Chronic Illness Therapy Measurement System\/Functional Assessment of Cancer Therapy, and 36-Item Short Form Survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This scoping literature review highlighted that a variety of PROMs are used in CML studies, including studies in the frontline setting. Different QOL aspects are measured by commonly used PROMs, and the choice of PROM is dependent on the study setting and objectives. A more comprehensive understanding of QOL gained by using appropriate PROMs will help optimize patient-centered treatment selection in CML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-025-00755-0","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:53:40Z","timestamp":1760500420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review"],"prefix":"10.1007","volume":"20","author":[{"given":"Kathryn E.","family":"Flynn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lovneet","family":"Saini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejal","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","unstructured":"Ning L, Hu C, Lu P, Que Y, Zhu X, Li D. Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Exp Hematol Oncol. 2020;3(1):29. https:\/\/doi.org\/10.1186\/s40164-020-00185-z","DOI":"10.1186\/s40164-020-00185-z"},{"key":"755_CR2","doi-asserted-by":"publisher","unstructured":"Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;1(10):1385\u2013415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047.","DOI":"10.6004\/jnccn.2020.0047"},{"key":"755_CR3","unstructured":"Eden RE, Coviello JM. Chronic Myelogenous Leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Updated January 16, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531459\/.\u00a0Accessed 13 June 2025"},{"key":"755_CR4","unstructured":"Cancer Stat Facts: Leukemia \u2014 Chronic Myeloid Leukemia (CML).\u00a0https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html.\u00a0Accessed 12 July 2024"},{"issue":"24","key":"755_CR5","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"20","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;20(24):2851\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866.","journal-title":"J Clin Oncol"},{"key":"755_CR6","doi-asserted-by":"publisher","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186\u201393. https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4.","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"755_CR7","doi-asserted-by":"publisher","unstructured":"Schoenbeck KL, Flynn KE. Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep. 2021;16(6):491\u20139. https:\/\/doi.org\/10.1007\/s11899-021-00656-y.","DOI":"10.1007\/s11899-021-00656-y"},{"key":"755_CR8","doi-asserted-by":"publisher","unstructured":"Shacham Abulafia A, Shemesh S, Rosenmann L, et al. Health-related quality of life in patients with chronic myeloid leukemia treated with first- versus second-generation tyrosine kinase inhibitors. J Clin Med. 2020;9(11):3417. https:\/\/doi.org\/10.3390\/jcm9113417","DOI":"10.3390\/jcm9113417"},{"key":"755_CR9","unstructured":"Schoenbeck K, Clements J, Demairo K, et al. Abstract at 66th ASH Annual Meeting & Exposition; December 7\u201310, 2024; San Diego, CA. Blood. 144:7913\u20134."},{"issue":"4","key":"755_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267030","volume":"17","author":"L Carfora","year":"2022","unstructured":"Carfora L, Foley CM, Hagi-Diakou P, et al. Patients\u2019 experiences and perspectives of patient-reported outcome measures in clinical care: a systematic review and qualitative meta-synthesis. PLoS One. 2022;17(4):e0267030. https:\/\/doi.org\/10.1371\/journal.pone.0267030.","journal-title":"PLoS One"},{"key":"755_CR11","doi-asserted-by":"publisher","unstructured":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79. https:\/\/doi.org\/10.1186\/1477-7525-4-79","DOI":"10.1186\/1477-7525-4-79"},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4137\/HSI.S11093","volume":"6","author":"T Weldring","year":"2013","unstructured":"Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61\u20138. https:\/\/doi.org\/10.4137\/HSI.S11093.","journal-title":"Health Serv Insights"},{"issue":"Suppl 2","key":"755_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-021-00374-2","volume":"12","author":"F Al Sayah","year":"2021","unstructured":"Al Sayah F, Jin X, Johnson JA. Selection of patient-reported outcome measures (PROMs) for use in health systems. J Patient Rep Outcomes. 2021;12(Suppl 2):99. https:\/\/doi.org\/10.1186\/s41687-021-00374-2.","journal-title":"J Patient Rep Outcomes"},{"issue":"5","key":"755_CR14","first-page":"264","volume":"6","author":"E Zagadailov","year":"2013","unstructured":"Zagadailov E, Fine M, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. Am Health Drug Benefits. 2013;6(5):264\u201374.","journal-title":"Am Health Drug Benefits"},{"issue":"Suppl-1","key":"755_CR15","doi-asserted-by":"publisher","DOI":"10.2174\/17450179-v17-e211118-2021-HT2-1910-12","volume":"19","author":"AE Nardi","year":"2023","unstructured":"Nardi AE, Sancassiani F, Barrui V, et al. The effects of tyrosine kinase inhibitors (TKIs) in monotherapy and with add-on treatments on health-related quality of life of people with chronic myeloid leukemia: a systematic review of randomized-controlled trials. Clin Pract Epidemiol Ment Health. 2023;19(Suppl-1):e1745017921112200. https:\/\/doi.org\/10.2174\/17450179-v17-e211118-2021-HT2-1910-12.","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"4","key":"755_CR16","doi-asserted-by":"publisher","first-page":"e220326","DOI":"10.1001\/jamahealthforum.2022.0326","volume":"3","author":"C Bull","year":"2022","unstructured":"Bull C, Teede H, Watson D, Callander EJ. Selecting and implementing patient-reported outcome and experience measures to assess health system performance. JAMA Health Forum. 2022; 3(4):e220326. https:\/\/doi.org\/10.1001\/jamahealthforum.2022.0326","journal-title":"JAMA Health Forum"},{"key":"755_CR17","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"755_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1446517","volume":"14","author":"B George","year":"2024","unstructured":"George B, Chan KH, Rios A. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy. Front Oncol. 2024;14:1446517. https:\/\/doi.org\/10.3389\/fonc.2024.1446517.","journal-title":"Front Oncol"},{"issue":"11","key":"755_CR19","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s11136-024-03761-6","volume":"33","author":"LB Mokkink","year":"2024","unstructured":"Mokkink LB, Elsman EBM, Terwee CB. COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0. Qual Life Res. 2024;33(11):2929\u201339. https:\/\/doi.org\/10.1007\/s11136-024-03761-6.","journal-title":"Qual Life Res"},{"key":"755_CR20","doi-asserted-by":"publisher","unstructured":"Smit Y, Metsemakers S, Janssen J, et al. Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures. Lancet Haematol. 2023;10(10):e849\u201359. https:\/\/doi.org\/10.1016\/S2352-3026(23)00173-4.","DOI":"10.1016\/S2352-3026(23)00173-4"},{"key":"755_CR21","doi-asserted-by":"publisher","unstructured":"Retraction Statement. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2023;25(9):889. https:\/\/doi.org\/10.1111\/jch.14718.","DOI":"10.1111\/jch.14718"},{"issue":"3","key":"755_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40271-024-00683-w","volume":"17","author":"A Gnanasakthy","year":"2024","unstructured":"Gnanasakthy A, DeMuro CR. The limitations of EQ-5D as a clinical outcome assessment tool. Patient. 2024;17(3):215\u20137. https:\/\/doi.org\/10.1007\/s40271-024-00683-w.","journal-title":"Patient"},{"key":"755_CR23","doi-asserted-by":"publisher","unstructured":"Jim HSL, Hyland KA, Nelson AM, et al. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: results from a pilot randomized trial. Cancer. 2020;126(1):174\u201380. https:\/\/doi.org\/10.1002\/cncr.32521","DOI":"10.1002\/cncr.32521"},{"key":"755_CR24","unstructured":"FACIT-Fatigue. https:\/\/www.facit.org\/measures\/facit-fatigue. Accessed 12 July 2024"},{"issue":"1","key":"755_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4699-5","volume":"18","author":"L Yu","year":"2018","unstructured":"Yu L, Wang H, Milijkovic D, et al. Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer. 2018;18(1):782. https:\/\/doi.org\/10.1186\/s12885-018-4699-5.","journal-title":"BMC Cancer"},{"issue":"8","key":"755_CR26","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371. https:\/\/doi.org\/10.1038\/leu.2016.104.","journal-title":"Leukemia"},{"key":"755_CR27","doi-asserted-by":"publisher","unstructured":"Giesinger JM, Efficace F, Aaronson N, et al. Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review. Value Health. 2021;24(4):585\u201391. https:\/\/doi.org\/10.1016\/j.jval.2020.11.004","DOI":"10.1016\/j.jval.2020.11.004"},{"issue":"3","key":"755_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s11136-013-0534-2","volume":"23","author":"AB Smith","year":"2014","unstructured":"Smith AB, Cocks K, Parry D, Taylor M. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G). Qual Life Res. 2014;23(3):971\u20136. https:\/\/doi.org\/10.1007\/s11136-013-0534-2","journal-title":"Qual Life Res"},{"key":"755_CR29","doi-asserted-by":"publisher","unstructured":"Wintner LM, Sztankay M, Aaronson N, et al. The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual. Eur J Cancer. 2016;68:73\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2016.08.024.","DOI":"10.1016\/j.ejca.2016.08.024"},{"issue":"1","key":"755_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-025-02387-7","volume":"3","author":"MJ Pilz","year":"2025","unstructured":"Pilz MJ, Thurner AMM, Storz LM, Krepper D, Giesinger JM. The current use and application of thresholds for clinical importance of the EORTC QLQ-C30, the EORTC CAT core and the EORTC QLQ-C15-PAL- a systematic scoping review. Health Qual Life Outcomes. 2025;3(1):55. https:\/\/doi.org\/10.1186\/s12955-025-02387-7.","journal-title":"Health Qual Life Outcomes"},{"key":"755_CR31","doi-asserted-by":"publisher","unstructured":"Cocks K, Wells JR, Johnson C, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2022.10.026.","DOI":"10.1016\/j.ejca.2022.10.026"},{"issue":"1","key":"755_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00275-w","volume":"7","author":"J Davda","year":"2021","unstructured":"Davda J, Kibet H, Achieng E, Atundo L, Komen T. Assessing the acceptability, reliability, and validity of the EORTC Quality of Life Questionnaire (QLQ-C30) in Kenyan cancer patients: a cross-sectional study. J Patient Rep Outcomes. 2021;7(1):4. https:\/\/doi.org\/10.1186\/s41687-020-00275-w","journal-title":"J Patient Rep Outcomes"},{"key":"755_CR33","unstructured":"EORTC Quality of Life Group. Manual for the use of EORTC measures in daily clinical practice. 2016."},{"key":"755_CR34","unstructured":"EORTC QLQ-C30 Scoring Manual. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf.\u00a0Accessed 12 July 2024"},{"issue":"11","key":"755_CR35","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol. 2003;21(11):2138\u201346. https:\/\/doi.org\/10.1200\/JCO.2003.12.154.","journal-title":"J Clin Oncol"},{"issue":"6","key":"755_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","volume":"52","author":"Z Aziz","year":"2011","unstructured":"Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma. 2011;52(6):1017\u201323. https:\/\/doi.org\/10.3109\/10428194.2011.560310","journal-title":"Leuk Lymphoma"},{"key":"755_CR37","unstructured":"MDASI Chronic Myeloid Leukemia Module. https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/departments-divisions\/symptom-research\/symptom-assessment-tools\/md-anderson-symptom-inventory-chronic-myeloid-leukemia-module.html. Accessed 12 July 2024"},{"key":"755_CR38","doi-asserted-by":"publisher","unstructured":"Williams L, Shi Q, Lin H, et al. Symptom severity cut points for the MD Anderson Symptom Inventory for CML (MDASI-CML). Blood. 2016;128(22):4765. https:\/\/doi.org\/10.1182\/blood.V128.22.4765.4765.","DOI":"10.1182\/blood.V128.22.4765.4765"},{"issue":"5","key":"755_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB, et al. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk. 2016;16(5):286\u201396. https:\/\/doi.org\/10.1016\/j.clml.2016.02.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"755_CR40","unstructured":"The MD Anderson Symptom Inventory User Guide Version 1. https:\/\/www.mdanderson.org\/content\/dam\/mdanderson\/documents\/Departments-and-Divisions\/Symptom-Research\/MDASI_userguide.pdf. Accessed 12 July 2024"},{"key":"755_CR41","unstructured":"What is the PRO-CTCAE Measurement System? https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/overview.html. Accessed 12 July 2024"},{"key":"755_CR42","unstructured":"Patient-Reported Outcomes Measurement Information System (PROMIS).\u00a0https:\/\/commonfund.nih.gov\/promis\/index. Accessed 12 July 2024"},{"key":"755_CR43","unstructured":"36-Item Short Form Survey Instrument (SF-36).\u00a0https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/survey-instrument.html. Accessed 12 July 2024"},{"key":"755_CR44","unstructured":"EORTC QLQ-C30 (version 3).\u00a0https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/08\/Specimen-QLQ-C30-English.pdf."},{"key":"755_CR45","unstructured":"Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE\u00ae). Quick Guide to the Item Library. Bethesda, MD: National Cancer Institute. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/item-library.pdf. Accessed June 2025"},{"issue":"10","key":"755_CR46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/acr.22025","volume":"65","author":"JE Broderick","year":"2013","unstructured":"Broderick JE, Schneider S, Junghaenel DU, Schwartz JE, Stone AA. Validity and reliability of patient-reported outcomes measurement information system instruments in osteoarthritis. Arthritis Care Res (Hoboken). 2013;65(10):1625\u201333. https:\/\/doi.org\/10.1002\/acr.22025.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"755_CR47","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.2196\/mhealth.9486","volume":"6","author":"KA Kessel","year":"2018","unstructured":"Kessel KA, Vogel MM, Alles A, et al. Mobile app delivery of the EORTC QLQ-C30 questionnaire to assess health-related quality of life in oncological patients: usability study. JMIR Mhealth Uhealth. 2018;6(2):e45. https:\/\/doi.org\/10.2196\/mhealth.9486.","journal-title":"JMIR Mhealth Uhealth"},{"key":"755_CR48","unstructured":"EORTC Quality of Life of Cancer Patients.\u00a0https:\/\/qol.eortc.org\/questionnaire\/eortc-qlq-c30\/.\u00a0Accessed 12 July 2024"},{"key":"755_CR49","unstructured":"Chronic Myeloid Leukaemia. https:\/\/qol.eortc.org\/questionnaire\/qlq-cml24\/.\u00a0Accessed 12 July 2024"},{"key":"755_CR50","unstructured":"Cancer related Fatigue. https:\/\/qol.eortc.org\/questionnaire\/qlq-fa12\/. Accessed 12 July 2024"},{"key":"755_CR51","doi-asserted-by":"crossref","unstructured":"Devlin N, Parkin D, Janssen B. Methods for analysing and reporting EQ-5D data. 2020.","DOI":"10.1007\/978-3-030-47622-9"},{"key":"755_CR52","unstructured":"EQ-5D-3L. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-3l\/.\u00a0Accessed 12 July 2024."},{"key":"755_CR53","unstructured":"EQ-5D-5L. https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l\/. Accessed 12 July 2024"},{"issue":"5","key":"755_CR54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087","journal-title":"Ann Med"},{"key":"755_CR55","unstructured":"EQ-5D-3L User Guide. https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-3LUserguide-23-07.pdf.\u00a0Accessed 12 July 2024"},{"key":"755_CR56","unstructured":"EQ-5D-5L User Guide. https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-5LUserguide-23-07.pdf. Accessed 12 July 2024"},{"key":"755_CR57","unstructured":"FACT-BRM. https:\/\/www.facit.org\/measures\/fact-brm. Accessed 12 July 2024"},{"key":"755_CR58","unstructured":"FACT-G. https:\/\/www.facit.org\/measures\/fact-g. Accessed 12 July 2024"},{"key":"755_CR59","unstructured":"FACT-Leu. https:\/\/www.facit.org\/measures\/fact-leu. Accessed 12 July 2024"},{"key":"755_CR60","unstructured":"TOI. https:\/\/www.facit.org\/scoring.\u00a0Accessed 12 July 2024"},{"issue":"1","key":"755_CR61","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67\u201374. https:\/\/doi.org\/10.1097\/00005650-198601000-00007.","journal-title":"Med Care"},{"key":"755_CR62","unstructured":"Morisky DE, DiMatteo MR. Morisky Medication-Taking Adherence Scale (4-item) (MMAS-4). https:\/\/eprovide.mapi-trust.org\/instruments\/morisky-medication-taking-adherence-scale-4-item.\u00a0Accessed 12 July 2024"},{"key":"755_CR63","unstructured":"Morisky D, Ang A, Krousel-Wood M, et al. Morisky Medication Adherence Scale (8-item) (MMAS-8).\u00a0https:\/\/eprovide.mapi-trust.org\/instruments\/morisky-medication-adherence-scale-8-item.\u00a0Accessed 12 July 2024"},{"issue":"2","key":"755_CR64","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1891\/1061-3749.26.2.E72","volume":"26","author":"KE Wickersham","year":"2018","unstructured":"Wickersham KE, Sereika SM, Kang HJ, et al. Use of a self-report medication adherence scale for measuring adherence to antiretroviral therapy in patients with HIV\/AIDS. J Nurs Meas. 2018;26(2):E72\u201388. https:\/\/doi.org\/10.1891\/1061-3749.26.2.E72.","journal-title":"J Nurs Meas"},{"key":"755_CR65","unstructured":"36-Item Short Form Survey (SF-36) Scoring Instructions.\u00a0https:\/\/www.rand.org\/health-care\/surveys_tools\/mos\/36-item-short-form\/scoring.html.\u00a0Accessed 12 July 2024"},{"key":"755_CR66","unstructured":"The SF-36v2 Health Survey. https:\/\/www.qualitymetric.com\/health-surveys\/the-sf-36v2-health-survey\/.\u00a0Accessed 12 July 2024"},{"key":"755_CR67","unstructured":"Medical Outcome Short Form (36) Health Survey.\u00a0https:\/\/www.clintools.com\/victims\/resources\/assessment\/health\/sf36.html.\u00a0Accessed 12 July 2024"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00755-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:20:13Z","timestamp":1769044813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00755-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00755-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KEF received honoraria from Novartis Pharmaceuticals Corporation. LS, AK, KJ, DY, and DW are Novartis employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}